This article discusses the recent successes in HIV prevention, particularly the results of two trials involving lenacapavir for pre-exposure prophylaxis (PrEP) in preventing HIV infection in various populations. The trials showed promising results, leading to a call for lenacapavir to become more accessible and affordable globally. Gilead, the company behind lenacapavir, recently announced agreements with generic manufacturers to make and sell the drug in 120 countries, but missed an opportunity to invest in manufacturing in sub-Saharan Africa. Additionally, the company’s anti-diversion clause excludes middle-income countries like Argentina, Brazil, Mexico, and Peru from purchasing generic versions of lenacapavir, limiting access to a potentially life-saving drug.
Source link
Lenacapavir: a giant step forward in HIV prevention—but a missed opportunity for achieving equity and access
